We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) closed the most recent trading day at $4.76, making no change from the previous trading session. This change lagged the S&P 500's 0.62% gain on the day. Meanwhile, the Dow gained 0.61%, and the Nasdaq, a tech-heavy index, added 1.05%.
Heading into today, shares of the company had lost 14.54% over the past month, lagging the Medical sector's gain of 1.66% and the S&P 500's gain of 3.85% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. The company is expected to report EPS of -$0.03, down 133.33% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $79.20 million, up 248.75% from the prior-year quarter.
ACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.09 per share and revenue of $443.77 million. These results would represent year-over-year changes of +59.09% and +124.05%, respectively.
Investors might also notice recent changes to analyst estimates for ACB. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 97.22% lower. ACB is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ACB in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know
Aurora Cannabis Inc. (ACB - Free Report) closed the most recent trading day at $4.76, making no change from the previous trading session. This change lagged the S&P 500's 0.62% gain on the day. Meanwhile, the Dow gained 0.61%, and the Nasdaq, a tech-heavy index, added 1.05%.
Heading into today, shares of the company had lost 14.54% over the past month, lagging the Medical sector's gain of 1.66% and the S&P 500's gain of 3.85% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. The company is expected to report EPS of -$0.03, down 133.33% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $79.20 million, up 248.75% from the prior-year quarter.
ACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.09 per share and revenue of $443.77 million. These results would represent year-over-year changes of +59.09% and +124.05%, respectively.
Investors might also notice recent changes to analyst estimates for ACB. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 97.22% lower. ACB is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ACB in the coming trading sessions, be sure to utilize Zacks.com.